Results 12,041-12,060 of 32,978 for speaker:Catherine Connolly
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: I read that. I am sorry, but I am out of time.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: Legal fees are one issue that needs to be dealt with. Prevention and minimising are the other side where governance and learning come in. On that, there is a statutory duty, is there not, to report all adverse clinical events?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: There is a 40% compliance rate with that, is that right, or has that gone up? That was in the chapter from the 2012 Comptroller and Auditor General report.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: What is the percentage now of the reporting under a statutory obligation?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: No, I would like to know whether the health entities and health enterprises – these are the new words and all the new language, whereas I talk about hospitals - are complying with that statutory duty now, given that there is a statutory duty to report. It was down at 40%.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: Is the State Claims Agency receiving 100% notification of adverse clinical events?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: So what Mr. McCarthy did was to look at the number of cases where they arose and then looked back to see if an adverse clinical event had occurred and been reported.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: And it was 40% of those cases.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: That is not the way I read it but I am glad Mr. McCarthy corrected it.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: I understand. I am trying to get to the essence of the questions when we are doing it. There is a statutory obligation on health enterprises to notify the State Claims Agency, is that right, or who do they notify?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: When an adverse clinical event arises.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: There is a little ambiguity there. In the sample cases, only 40% had complied with that duty. Is Mr. Breen in a position now to say what the position is?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: Okay. On the estimate of the future liability, and it has been clearly outlined how much it has jumped - more than double in the case of the clinical indemnity scheme - there was a 20% margin of error in the chapter going back to 2012. The State Claims Agency allowed for a 20% margin of comfort, which I can understand, and there were certain reasons for that such as there might be...
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: I understand what the agency has said because I have read it. It was in terms of what the Comptroller and Auditor General's report was saying. Is Mr. McCarthy happy with that?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: Okay. On the Mediation Act, I understand that there is an obligation now. Actually, it is not an obligation. Will Mr. Breen clarify the obligation or what the appropriate terminology is under the Mediation Act for people?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: Or can he take cognisance of the fact that there was no mediation?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: Okay. On the Mediation Act, has Mr. Breen noticed a difference in terms of cases going to mediation? Is he in a position to quantify the effect of that Act?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: The jury is still out on that one.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: Okay. I come back again to the feedback mechanism. The agency gives a report back to each hospital. They give the agency whatever percentage of the adverse clinical events, and then the agency goes back to them with a report of the total amount. Is that right?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: And the agency discusses that with them with a view to learning from it. Is that correct?